James W. Breyer

James W. Breyer is a prominent venture capitalist and technology investor, known for his early investments in companies like Facebook and his role in the development of the digital economy. He is the founder and CEO of Breyer Capital, a firm that focuses on technology investments and has contributed to various successful startups. Breyer is often sought after for his insights into venture capital and innovation, and he has a reputation for being cautious in funding projects that lack scientific credibility, as evidenced by his decision to decline investment in Billy Evans's new blood-testing startup, which he criticized for its lack of 'scientific defensibility and clinical utility.'